title: Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
abstract: We investigated the role of 4-1BB, a T cell co-stimulatory molecule, in alloimmune responses. In vivo mixed lymphocyte reactions showed that 4-1BB was preferentially expressed on actively dividing CD4(+) and CD8(+) T cells. Furthermore, following alloantigen challenge, the draining lymph nodes contained subpopulations of 4-1BB-expressing CD4(+) and CD8(+) T cells. 4-1BB-deficient C57BL/6 mice showed a delayed rejection of cardiac transplants mismatched for the major histocompatibility complex. Longer transplant survival was induced by blockade of 4-1BB/4-1BB ligand (4-1BBL) interactions using an anti-4-1BBL monoclonal antibody. Histological analysis showed that prolonged transplant survival in the 4-1BB-deficient and anti-4-1BBL-treated mice correlated with reduced lymphocytic infiltration and vasculitis in the donor heart tissue. Taken together, our data suggest that blockade of 4-1BB/4-1BBL interactions inhibited the expansion of alloreactive T cells and reduced CTL activity against host alloantigen, which in turn resulted in the prolongation of allograft survival. Blockade of the 4-1BB co-stimulatory pathway may be useful for preventing allograft rejection.
authors.affiliation: Immunomodulation Research Center, University of Ulsan, 682-714, Ulsan, Korea.
authors.forename: H R
authors.initials: HR
authors.lastname: Cho
authors.forename: B
authors.initials: B
authors.lastname: Kwon
authors.forename: H
authors.initials: H
authors.lastname: Yagita
authors.forename: S
authors.initials: S
authors.lastname: La
authors.forename: E A
authors.initials: EA
authors.lastname: Lee
authors.forename: J-E
authors.initials: JE
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Akiba
authors.forename: J
authors.initials: J
authors.lastname: Kim
authors.forename: J-H
authors.initials: JH
authors.lastname: Suh
authors.forename: D S
authors.initials: DS
authors.lastname: Vinay
authors.forename: S-A
authors.initials: SA
authors.lastname: Ju
authors.forename: B-S
authors.initials: BS
authors.lastname: Kim
authors.forename: R S
authors.initials: RS
authors.lastname: Mittler
authors.forename: K
authors.initials: K
authors.lastname: Okumura
authors.forename: B S
authors.initials: BS
authors.lastname: Kwon
mesh_terms: D053330:4-1BB Ligand; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015703:Antigens, CD; D002455:Cell Division / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D007519:Isoantigens / Q000276:immunology / Q000378:metabolism; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008817:Mice, Mutant Strains; D017475:Receptors, Nerve Growth Factor / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology; D016038:Skin Transplantation / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D014184:Transplantation, Homologous; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D053330:4-1BB Ligand; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D007519:Isoantigens; D017475:Receptors, Nerve Growth Factor; D018124:Receptors, Tumor Necrosis Factor; C505715:Tnfrsf9 protein, mouse; C505975:Tnfsf9 protein, mouse; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D014409:Tumor Necrosis Factor-alpha